View Financial HealthBeta Systems Software 배당 및 자사주 매입배당 기준 점검 0/6Beta Systems Software 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 13+ 1 more updateSparta AG, Annual General Meeting, Apr 22, 2026Sparta AG, Annual General Meeting, Apr 22, 2026, at 10:30 W. Europe Standard Time.공시 • Feb 09Sparta AG, Annual General Meeting, Mar 18, 2025Sparta AG, Annual General Meeting, Mar 18, 2025, at 11:30 W. Europe Standard Time.공시 • Sep 18Diatreme Resources Limited (ASX:DRX) acquired Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million.Diatreme Resources Limited (ASX:DRX) made an offer to acquire Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million on February 16, 2024. exchange ratio for the consideration is 1.3319. As of May 21, 2024 minimum tender condition was fulfilled. As of May 24, 2024 Diatreme Resources Limited is encouraging all Metallica shareholders to Accept the Offer and has amassed a 57 per cent stake in Metallica, Turning the deal hostile. Transaction is expected to complete on June 11, 2024. As of announcement on June 3, 2024, the deal is expected to be completed on June 14, 2024. As of July 4, 2024, Diatreme Resources holds 71.28% stake in Metallica Minerals and the offer will get closed on July 9, 2024. As of Diatreme Resources holds 79.67% stake in Metallica Minerals and the offer will get closed on July 23, 2024. Transaction has been approved by Diatreme Resources Limited's Board of director's. Transaction will be completed on August 6, 2024. As on July 24, 2024, Diatreme Resources has now acquired a relevant interest in more than 90% of Metallica Shares and more than 75% of the Metallica Shares that it offered to acquire under the Offer. The Offer is due to close on 6 August 2024 and will not be extended further by Diatreme. Subject to the terms of the Offer, Metallica Shareholders who accept the Offer before the closing date will receive the Offer Consideration within 10 Business Days of acceptance. Given Diatreme’s relevant interest in Metallica is now more than 90%, Diatreme will seek to compulsorily acquire any outstanding Metallica Shares. As on August 16, 2024, Metallica Minerals will be removed from the Official List at the close of trading on Friday, 16 August 2024, following compulsory acquisition of its remaining securities by Diatreme Resources Limited. KPMG Financial Advisory Services (Australia) Pty Limited acted as Financial advisor and Mccullough Robertson Lawyers and GRE Capital Pty Ltd acted as legal advisor to Diatreme Resources Limited (ASX:DRX). Jones Day (Australia) acted as legal advisor to Ilwella Pty Ltd and Market Eye Pty Ltd acted as registrar to Diatreme. Rodd Levy and Jason Jordan of Herbert Smith Freehills acted as legal advisor to Diatreme Resources. Diatreme Resources Limited (ASX:DRX) completed the acquisition of Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million on September 18, 2024. As at close of the takeover offer period on 6 August 2024, Diatreme Resources Limited had a relevant interest in 92.7% of Metallica Minerals Limited shares. Following completion of the compulsory acquisition process, Diatreme Resources Limited now has a relevant interest in 100% of Metallica Minerals Limited shares.Reported Earnings • Aug 18First half 2024 earnings released: €1.80 loss per share (vs €2.72 loss in 1H 2023)First half 2024 results: €1.80 loss per share (improved from €2.72 loss in 1H 2023). Net loss: €8.67m (loss narrowed 9.3% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 29Full year 2023 earnings releasedFull year 2023 results: Net loss: €14.7m (loss narrowed 64% from FY 2022).New Risk • Apr 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.0m (US$95.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€90.0m market cap, or US$95.8m).New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).New Risk • Nov 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €85.1m (US$93.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€85.1m market cap, or US$93.0m).Reported Earnings • Aug 03First half 2023 earnings released: €2.72 loss per share (vs €15.73 loss in 1H 2022)First half 2023 results: €2.72 loss per share (improved from €15.73 loss in 1H 2022). Net loss: €9.55m (loss narrowed 70% from 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.Reported Earnings • Jun 07Full year 2022 earnings releasedFull year 2022 results: Net loss: €40.4m (loss widened €39.9m from FY 2021).Buying Opportunity • May 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €39.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 76% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Aug 02First half 2022 earnings releasedFirst half 2022 results: Net income: (down €4.44m from profit in 1H 2021).Reported Earnings • May 04Full year 2021 earnings releasedFull year 2021 results: Revenue: €3.26m (down 46% from FY 2020). Net loss: €507.5k (down 103% from profit in FY 2020).Reported Earnings • Aug 18First half 2021 earnings releasedThe company reported a soft first half result with weaker earnings and revenues, although profit margins were improved. First half 2021 results: Revenue: €5.60m (down 1,114% from 1H 2020). Net income: €4.44m (down 51% from 1H 2020). Profit margin: 79% (up from net loss in 1H 2020). The move to profitability was driven by lower revenue.Reported Earnings • May 01Full year 2020 earnings releasedFull year 2020 results: Revenue: €15.9m (up 106% from FY 2019). Net income: €15.9m (up €15.5m from FY 2019).Is New 90 Day High Low • Feb 20New 90-day low: €74.00The company is down 27% from its price of €102 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 13% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: €111The company is up 8.0% from its price of €103 on 07 October 2020. The German market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. Its price trend is also similar to the Capital Markets industry, which is up 8.0% over the same period.Is New 90 Day High Low • Sep 26New 90-day low: €96.00The company is down 5.0% from its price of €101 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Capital Markets industry, which is down 8.0% over the same period.공시 • Sep 23Sparta AG (DB:SPT6) made an offer to acquire remaining 95.8% stake in 4basebio AG (XTRA:4BSB) for €92.3 million.Sparta AG (DB:SPT6) made an offer to acquire remaining 95.8% stake in 4basebio AG (XTRA:4BSB) for €92.3 million on July 27, 2020. Under the terms, the shares will be acquired at a price of €2 per share. The acceptance period runs from September 1, 2020 to September 29, 2020. The management board and supervisory board of 4basebio consider the amount of the offer consideration by the bidder to be appropriate. Thorsten Kuthe, Meike Dresler-Lenz, Stefan Westerheide, Lena Pfeufer and Michael Neises of Heuking Kühn Lüer Wojtek acted as legal advisor to 4basebio AG.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 SPT6 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: SPT6 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Beta Systems Software 배당 수익률 vs 시장SPT6의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SPT6)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Capital Markets)2.9%분석가 예측 (SPT6) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SPT6 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SPT6 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SPT6 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: SPT6 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 18:32종가2026/05/20 00:00수익2024/09/30연간 수익2024/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Beta Systems Software Aktiengesellschaft는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Adam JakubowskiSMC Research
공시 • Mar 13+ 1 more updateSparta AG, Annual General Meeting, Apr 22, 2026Sparta AG, Annual General Meeting, Apr 22, 2026, at 10:30 W. Europe Standard Time.
공시 • Feb 09Sparta AG, Annual General Meeting, Mar 18, 2025Sparta AG, Annual General Meeting, Mar 18, 2025, at 11:30 W. Europe Standard Time.
공시 • Sep 18Diatreme Resources Limited (ASX:DRX) acquired Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million.Diatreme Resources Limited (ASX:DRX) made an offer to acquire Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million on February 16, 2024. exchange ratio for the consideration is 1.3319. As of May 21, 2024 minimum tender condition was fulfilled. As of May 24, 2024 Diatreme Resources Limited is encouraging all Metallica shareholders to Accept the Offer and has amassed a 57 per cent stake in Metallica, Turning the deal hostile. Transaction is expected to complete on June 11, 2024. As of announcement on June 3, 2024, the deal is expected to be completed on June 14, 2024. As of July 4, 2024, Diatreme Resources holds 71.28% stake in Metallica Minerals and the offer will get closed on July 9, 2024. As of Diatreme Resources holds 79.67% stake in Metallica Minerals and the offer will get closed on July 23, 2024. Transaction has been approved by Diatreme Resources Limited's Board of director's. Transaction will be completed on August 6, 2024. As on July 24, 2024, Diatreme Resources has now acquired a relevant interest in more than 90% of Metallica Shares and more than 75% of the Metallica Shares that it offered to acquire under the Offer. The Offer is due to close on 6 August 2024 and will not be extended further by Diatreme. Subject to the terms of the Offer, Metallica Shareholders who accept the Offer before the closing date will receive the Offer Consideration within 10 Business Days of acceptance. Given Diatreme’s relevant interest in Metallica is now more than 90%, Diatreme will seek to compulsorily acquire any outstanding Metallica Shares. As on August 16, 2024, Metallica Minerals will be removed from the Official List at the close of trading on Friday, 16 August 2024, following compulsory acquisition of its remaining securities by Diatreme Resources Limited. KPMG Financial Advisory Services (Australia) Pty Limited acted as Financial advisor and Mccullough Robertson Lawyers and GRE Capital Pty Ltd acted as legal advisor to Diatreme Resources Limited (ASX:DRX). Jones Day (Australia) acted as legal advisor to Ilwella Pty Ltd and Market Eye Pty Ltd acted as registrar to Diatreme. Rodd Levy and Jason Jordan of Herbert Smith Freehills acted as legal advisor to Diatreme Resources. Diatreme Resources Limited (ASX:DRX) completed the acquisition of Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million on September 18, 2024. As at close of the takeover offer period on 6 August 2024, Diatreme Resources Limited had a relevant interest in 92.7% of Metallica Minerals Limited shares. Following completion of the compulsory acquisition process, Diatreme Resources Limited now has a relevant interest in 100% of Metallica Minerals Limited shares.
Reported Earnings • Aug 18First half 2024 earnings released: €1.80 loss per share (vs €2.72 loss in 1H 2023)First half 2024 results: €1.80 loss per share (improved from €2.72 loss in 1H 2023). Net loss: €8.67m (loss narrowed 9.3% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 29Full year 2023 earnings releasedFull year 2023 results: Net loss: €14.7m (loss narrowed 64% from FY 2022).
New Risk • Apr 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.0m (US$95.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€90.0m market cap, or US$95.8m).
New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).
New Risk • Nov 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €85.1m (US$93.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€85.1m market cap, or US$93.0m).
Reported Earnings • Aug 03First half 2023 earnings released: €2.72 loss per share (vs €15.73 loss in 1H 2022)First half 2023 results: €2.72 loss per share (improved from €15.73 loss in 1H 2022). Net loss: €9.55m (loss narrowed 70% from 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jun 07Full year 2022 earnings releasedFull year 2022 results: Net loss: €40.4m (loss widened €39.9m from FY 2021).
Buying Opportunity • May 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €39.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 76% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Aug 02First half 2022 earnings releasedFirst half 2022 results: Net income: (down €4.44m from profit in 1H 2021).
Reported Earnings • May 04Full year 2021 earnings releasedFull year 2021 results: Revenue: €3.26m (down 46% from FY 2020). Net loss: €507.5k (down 103% from profit in FY 2020).
Reported Earnings • Aug 18First half 2021 earnings releasedThe company reported a soft first half result with weaker earnings and revenues, although profit margins were improved. First half 2021 results: Revenue: €5.60m (down 1,114% from 1H 2020). Net income: €4.44m (down 51% from 1H 2020). Profit margin: 79% (up from net loss in 1H 2020). The move to profitability was driven by lower revenue.
Reported Earnings • May 01Full year 2020 earnings releasedFull year 2020 results: Revenue: €15.9m (up 106% from FY 2019). Net income: €15.9m (up €15.5m from FY 2019).
Is New 90 Day High Low • Feb 20New 90-day low: €74.00The company is down 27% from its price of €102 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 13% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: €111The company is up 8.0% from its price of €103 on 07 October 2020. The German market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. Its price trend is also similar to the Capital Markets industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Sep 26New 90-day low: €96.00The company is down 5.0% from its price of €101 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Capital Markets industry, which is down 8.0% over the same period.
공시 • Sep 23Sparta AG (DB:SPT6) made an offer to acquire remaining 95.8% stake in 4basebio AG (XTRA:4BSB) for €92.3 million.Sparta AG (DB:SPT6) made an offer to acquire remaining 95.8% stake in 4basebio AG (XTRA:4BSB) for €92.3 million on July 27, 2020. Under the terms, the shares will be acquired at a price of €2 per share. The acceptance period runs from September 1, 2020 to September 29, 2020. The management board and supervisory board of 4basebio consider the amount of the offer consideration by the bidder to be appropriate. Thorsten Kuthe, Meike Dresler-Lenz, Stefan Westerheide, Lena Pfeufer and Michael Neises of Heuking Kühn Lüer Wojtek acted as legal advisor to 4basebio AG.